Aberrant pre-mRNA splicing regulation in the development of hepatocellular carcinoma

Abstract

Alternative splicing is a highly regulated process that plays a critical role in diversification of the transcriptome and proteome in the cell. Several diseases, including different types of cancers, have been associated with aberrant regulation of alternative splicing. Thus, correcting alternative splicing is an attractive strategy to restore normal cell physiology in patients with cancer including hepatocellular carcinoma (HCC). This review summarizes the role of alternative splicing events related to HCC and potential therapeutic applications for it.

Keywords

Alternative splicing / hepatocellular carcinoma / splicing factors

References

[1] Siegel RL,Jemal A.Cancer statistics, 2017.CA Cancer J Clin2017;67:7-30

[2] El-Serag HB.Hepatocellular carcinoma.N Engl J Med2011;365:1118-27

[3] Jemal A,Center MM,Ward E.Global cancer statistics.CA Cancer J Clin2011;61:69-90

[4] Zucman-Rossi J.Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies.Pharmacogenomics2007;8:997-1003

[5] Singh RK.Pre-mRNA splicing in disease and therapeutics.Trends Mol Med2012;18:472-82 PMCID:PMC3411911

[6] Wang ET,Luo S,Zhang L,Kingsmore SF,Burge CB.Alternative isoform regulation in human tissue transcriptomes.Nature2008;456:470-6 PMCID:PMC2593745

[7] Pan Q,Lee LJ,Blencowe BJ.Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing.Nat Genet2008;40:1413-5

[8] Yang X,Kang S,Hao T,Sun S,Shen YA,Spirohn K,Duran-Frigola M,Pevzner SJ,Trigg SA,Ghamsari L,Yi S,Balcha D,Costanzo M,Boone C,Salehi-Ashtiani K,Chen AA,Aloy P,Hill DE,Xia Y.Widespread expansion of protein interaction capabilities by alternative splicing.Cell2016;164:805-17 PMCID:PMC4882190

[9] Chabot B.Directing alternative splicing: cast and scenarios.Trends Genet1996;12:472-8

[10] Lee Y.Mechanisms and regulation of alternative pre-mRNA splicing.Annu Rev Biochem2015;84:291-323 PMCID:PMC4526142

[11] Barreau C,Mereau A.Mammalian CELF/Bruno-like RNA-binding proteins: molecular characteristics and biological functions.Biochimie2006;88:515-25

[12] Sutherland LC,White RD.RNA binding motif (RBM) proteins: a novel family of apoptosis modulators?.J Cell Biochem2005;94:5-24

[13] David CJ.Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.Genes Dev2010;24:2343-64 PMCID:PMC2964746

[14] Dominguez D,Weatheritt R,Blencowe BJ.An extensive program of periodic alternative splicing linked to cell cycle progression.Elife2016;5:

[15] Oltean S.Hallmarks of alternative splicing in cancer.Oncogene2014;33:5311-8

[16] Berasain C,Castillo J,Prieto J.Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences.World J Gastroenterol2010;16:3091-102 PMCID:PMC2896746

[17] Zhang L,Zhang X.Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets.Mol Genet Genomics2016;291:1035-51

[18] Liu XN,Wang TT,Sun SH.An alternative POLDIP3 transcript promotes hepatocellular carcinoma progression.Biomed Pharmacother2017;89:276-83

[19] Lu Y,Ji J,Sourbier C,Qu J,Wang C,Chen Y,Xu M,Lee S,Linehan WM,Yang Y.Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma.Hepatology2015;62:1122-31 PMCID:PMC4589429

[20] Chettouh H,Aoudjehane L,Claperon A,Rey C,Soubrane O,Praz F,Rosmorduc O.Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.Cancer Res2013;73:3974-86

[21] Zhang J,Wei J,Yang D,Chen GG.Alternative splicing of estrogen receptor alpha in hepatocellular carcinoma.BMC Cancer2016;16:926 PMCID:PMC5129602

[22] Endo K.Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival.J Hepatol2000;32:78-84

[23] Chae S,Lee EG,Lee DC,Park KC,Kim KW.Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines.Int J Oncol2009;35:1409-16

[24] Koga H,Tomimaru Y,Lee HC,Yano H,Kim M.Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling.PLoS One2012;7:e39981 PMCID:PMC3386968

[25] Liu L,Zhang C.Aberrant regulation of alternative pre-mRNA splicing in hepatocellular carcinoma.Crit Rev Eukaryot Gene Expr2014;24:133-49

[26] Lu X,Man X,Tang L,Zhang F,Huang Q,Liu Y,Chen Z.Aberrant splicing of Hugl-1 is associated with hepatocellular carcinoma progression.Clin Cancer Res2009;15:3287-96

[27] Castillo J,Latasa MU,Calvo A,Bioulac-Sage P,Prieto J,Berasain C.Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform DeltaEx2p73 in human hepatocellular tumors.Gastroenterology2009;137:1805-15

[28] Stiewe T,Frilling A,Putzer BM.Transactivation-deficient DeltaTA-p73 acts as an oncogene.Cancer Res2002;62:3598-602

[29] Yea S,Zhao X,Tal-Kremer S,Villanueva A,Tarocchi M,Shirasawa S,Martignetti JA,Friedman SL.Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.Gastroenterology2008;134:1521-31 PMCID:PMC2600656

[30] Danan-Gotthold M,Eisenberg E,Karni R.Identification of recurrent regulated alternative splicing events across human solid tumors.Nucleic Acids Res2015;43:5130-44 PMCID:PMC4446417

[31] Zhou X,Cheng Y,Xie Z,Han J,Fang J.BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells.Nat Commun2014;5:4581

[32] Anczukow O,Clery A,Shen C,Raimer A,Jensen MA,Allain FH.SRSF1-regulated alternative splicing in breast cancer.Mol Cell2015;60:105-17 PMCID:PMC4597910

[33] Sen S,Webster NJ.SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing.Mol Cell Biol2009;29:871-80 PMCID:PMC2630670

[34] Talukdar I,Urbano R,Yates JR3rd.hnRNP A1 and hnRNP F modulate the alternative splicing of exon 11 of the insulin receptor gene.PLoS One2011;6:e27869 PMCID:PMC3223206

[35] Webster NJG.Alternative RNA splicing in the pathogenesis of liver disease.Front Endocrinol (Lausanne)2017;8:133 PMCID:PMC5478874

[36] Sen S,Jumaa H.Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice.Hepatology2015;61:171-83 PMCID:PMC4280350

[37] Lee JS,Libbrecht L,Kaposi-Novak P,Mikaelyan A,Demetris AJ,Nevens F,Thorgeirsson SS.A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.Nat Med2006;12:410-6

[38] Becker D,Krupp M,Gerhold-Ay A,Binder H,Maass T,Galle PR.Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC.Mol Cancer2012;11:55 PMCID:PMC3583209

[39] Bhate A,Bebee TW,Arif W,Chorghade S,Lee JH,Carstens RP,Kalsotra A.ESRP2 controls an adult splicing programme in hepatocytes to support postnatal liver maturation.Nat Commun2015;6:8768 PMCID:PMC4635967

[40] Elizalde M,Azkona M,Goni S,Uriarte I,Collantes M,Lujambio A,Avila MA.Splicing regulator SLU7 is essential for maintaining liver homeostasis.J Clin Invest2014;124:2909-20 PMCID:PMC4071377

[41] Urtasun R,Azkona M,Garcia-Irigoyen O,Fernandez-Barrena MG,Alonso MM,Prieto J,Berasain C.Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression.Oncogene2016;35:4719-29

[42] Sen S,Webster NJ.Splicing factor SRSF3 is crucial for hepatocyte differentiation and metabolic function.Nat Commun2013;4:1336 PMCID:PMC4314219

[43] Wu S,Gao C,Wen J.The role of XBP1s in the metastasis and prognosis of hepatocellular carcinoma.Biochem Biophys Res Commun2018;500:530-7

[44] Yuan JH,Wang TT,Tao QF,Wang F.The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1.Nat Cell Biol2017;19:820-32

[45] Lin KT,Chau GY,Huang CY.Identification of latent biomarkers in hepatocellular carcinoma by ultra-deep whole-transcriptome sequencing.Oncogene2014;33:4786-94

[46] Wood M,McClorey G.Modulating the expression of disease genes with RNA-based therapy.PLoS Genet2007;3:e109 PMCID:PMC1904251

[47] Havens MA.Splice-switching antisense oligonucleotides as therapeutic drugs.Nucleic Acids Res2016;44:6549-63 PMCID:PMC5001604